Transcription of the human folylpoly-gamma-glutamate synthetase gene.
In mammals, folylpoly-gamma-glutamate synthetase (FPGS) activity is found in any cell undergoing sustained proliferative phases, but this enzyme also displays a tissue-specific pattern of expression in differentiated tissues. It is now reported that the steady state levels of FPGS mRNA in normal and neoplastic cells reflect these patterns, supporting the concept that the control mechanisms underlying this distribution are transcriptional. To initiate an understanding of these interacting levels of control, we have determined the position and properties of the minimal FPGS promoter controlling transcription of the FPGS gene in human CEM leukemia cells, a line which expresses high levels of this enzyme and its mRNA. The TATA-less region immediately upstream of the major transcriptional start site previously mapped in human tumor cells, which includes several GC- and Y-boxes, functioned as a remarkably efficient promoter when used to drive expression of a luciferase reporter in transient expression studies in CEM cells. The minimal region of the FPGS promoter required for maximal transcriptional activation in CEM cells included the 80 base pairs over which the multiple transcriptional start sites were located, and the 43 base pairs immediately upstream. DNase I footprint analysis detected the binding of Sp1 at all seven of the consensus sites within the probe used, two of which are contained within the minimal promoter region. The several Sp1 sites immediately upstream of the first major transcriptional start activated transcription in Drosophila cells when cotransfected with an Sp1 construct, including those in the region which functioned as a minimal promoter in CEM cells. An additional region of the minimal promoter, situated between the two translational start codons of the FPGS gene, was bound by protein(s) from HeLa cell nuclear extracts. We conclude that transcription of the FPGS gene in CEM cells involves transactivation events over a limited upstream DNA sequence and that the FPGS promoter used in proliferating human leukemic cells has strong similarity to other TATA-less promoters that utilize tandem, closely spaced Sp1 sites to initiate transcription.
Freemantle
S J
SJ
Department of Pharmacology and Toxicology and the Massey Cancer Center, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia 23298, USA.
Moran
R G
RG
D000818:Animals; D001483:Base Sequence; D003062:Codon; D015342:DNA Probes; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D017930:Genes, Reporter; D006367:HeLa Cells; D006801:Humans; D007938:Leukemia; D051379:Mice; D008969:Molecular Sequence Data; D010453:Peptide Synthases / Q000096:biosynthesis* / Q000235:genetics*; D016133:Polymerase Chain Reaction; D011401:Promoter Regions, Genetic; D014176:Protein Biosynthesis; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis; D012045:Regulatory Sequences, Nucleic Acid; D016415:Sequence Alignment; D012689:Sequence Homology, Nucleic Acid; D014158:Transcription, Genetic; D015533:Transcriptional Activation; D014407:Tumor Cells, Cultured
D003062:Codon; D015342:DNA Probes; D011993:Recombinant Fusion Proteins; D010453:Peptide Synthases; C023103:folylpolyglutamate synthetase